Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
| Global Basal Cell Carcinoma Treatment Market Analysis & Forecast 2024-2034, Featuring Cybin, Numinus, Revive Therapeutics, NRx Pharmaceuticals & Mind Medicine | ||
| By: PR Newswire Association LLC. - 01 Feb 2024 | Back to overview list |
|
|
DUBLIN, Feb. 1, 2024 /PRNewswire/ -- The "Global Basal Cell Carcinoma Treatment Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering.  The recent in-depth analysis of the global basal cell carcinoma treatment market projects a soaring growth trajectory, estimated to burgeon from USD 7.36 billion in 2023 to USD 17.38 billion by the year 2034. This growth, characterized by a substantial compound annual growth rate (CAGR) of 8.12% during the 2024-2034 period, is largely driven by increasing occurrences of basal cell carcinoma, coupled with innovative advancements in treatment options. The most common form of non-melanoma skin cancer, basal cell carcinoma, has been the subject of intensive research and development efforts. As a result, new treatment options are emerging, such as AiViva Biopharma's recent promising trial outcomes for AIV001 (Axitinib), an innovative intradermal therapy for patients diagnosed with basal cell carcinoma. Efforts like these are integral components propelling the market's expansion. The global basal cell carcinoma treatment market's dynamic growth finds a strong base in end-user segments, especially within hospital settings. Hospitals remain essential for patient care, interdisciplinary collaboration, and spearheading treatment innovations. Specialist clinics are also expected to manifest considerable growth rates due to their targeted and specialized treatment approaches. The regional analysis indicates North America as the leader in revenue generation for the forecast period, driven by high instances of skin cancers, robust research initiatives, and favorable reimbursement landscapes. However, the Asia Pacific region is not far behind, forecasted to register the fastest CAGR on the heels of an uptick in skin disease cases, treatment awareness, and international collaborations.
End-User Segmentation Emphasizes Critical Role of Hospitals
The comprehensive global basal cell carcinoma treatment market analysis is formulated to aid stakeholders in discerning the nuanced intricacies of market dynamics, high-growth sectors, and the potent strategies adopted by market players that align with current trends and future projections.
For more information about this report visit https://www.researchandmarkets.com/r/8i9aoh About ResearchAndMarkets.com Media Contact: Research and Markets For E.S.T Office Hours Call +1-917-300-0470 U.S. Fax: 646-607-1904 Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg SOURCE Research and Markets 
|
||
|
|
||
 | Back to overview list | |
View original content: